Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details)

v3.23.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 31, 2023
May 31, 2022
Mar. 10, 2023
Feb. 28, 2023
Summary Of Significant Accounting Policies [Line Items]        
Net loss $ (79,824) $ (210,820)    
Accumulated deficit (841,690) (766,131)    
Balance in excess of federally insured limits 2,300 4,000    
Restricted cash, uninsured amount 5,500      
Restricted cash 6,507      
Charge to APIC due to warrant modification 2,200      
Amortization of Debt Issuance Costs 9,747 $ 87    
Warrant expirations deemed dividend $ 5,400      
Bulk Drug Substance        
Summary Of Significant Accounting Policies [Line Items]        
Shelf life 4 years      
Extended shelf life 4 years      
Private Equity Offering        
Summary Of Significant Accounting Policies [Line Items]        
Debt issuance costs $ 9,700      
Surety Bond Backstop Agreement        
Summary Of Significant Accounting Policies [Line Items]        
Amortization of Debt Issuance Costs $ 400      
Amount of cash collateral to be relieved of amount currently pledged     $ 1,400 $ 5,100